1. Guillermo J. Tearney

    0 Comments Related Articles

    1. Login to comment.

  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Guillermo J. Tearney

    Guillermo J. Tearney

    Guillermo Tearney M.D., Ph.D. is Professor of Pathology at Harvard Medical School, an Affiliated Faculty member of the Harvard-MIT Division of Health Sciences and Technology (HST), and the Associate Director of the Wellman Center for Photomedicine at the Massachusetts Genera lHospital. Dr. Tearney received his MD magna cum laude from Harvard Medical School and received his PhD in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.

     

    Dr. Tearney’s research interests are focused on the development and clinical validation of non-invasive, high-resolution optical imaging methods for disease diagnosis. Dr. Tearney's lab was the first to perform human imaging in the coronary arteries and gastrointestinal tract in vivo with Optical Coherence Tomography (OCT), which provides cross-sectional images of tissue architectural microstructure at a resolution of 10 μm. He has also conducted many of the seminal studies validating OCT and is considered an expert on OCT image interpretation. Recently, Dr. Tearney's lab has invented a next generation OCT technology, termed μOCT, which has a resolution of 1 μm and is capable of imaging cells and sub cellular structures in the coronary wall. Dr. Tearney has also developed several other technologies, including a confocal endomicroscope capable of imaging the entire esophagus, an ultraminiature three-dimensional endoscope, a highly efficient form of near field scanning optical microscopy (NSOM), and novel fluorescence spectroscopy and multimodality imaging techniques. He has an active program in Raman spectroscopy and has conducted the first intracoronary Raman in vivo. Dr. Tearney is co-editor of The Handbook of Optical Coherence Tomorgraphy and has written over 170 peer-reviewed publications, including papers that have been highlighted on the covers of Science, Nature Medicine, Circulation, Gastroenterology, and Journal of American College of Cardiology.

     

    Dr. Tearney’s work extends beyond his laboratory at MGH, many of his technologies are being produced commercially and he has founded the International Working Group on Intracoronary OCT Standardization and Validation, a group that is dedicated to establishing standards to ensure the widespread adoption of this imaging technology

  3. Quotes

    1. We’ve done a lot of benchtop imaging with micro-OCT, but this is the first time we’ve been able to use it in people...It’s unprecedented to see this pathophysiology dynamically in living patients. It will allow us to begin to understand things we never even knew were there.
      In Innovative tool gives researchers new look at the nasal airway in CF patients
    2. Coronary imaging has rapidly evolved over the past decade and has become an important part of the practice of diagnostic and interventional cardiology...I’m looking forward to once again collaborating with Infraredx who pioneered the development of the only FDA-cleared dual-modality NIRS-IVUS device which is playing a vital role in furthering our understanding of the vulnerable plaque and its correlation to future coronary events. Our partnership will focus on ways to harness the collective value of current imaging modalities in order to provide clinicians with more comprehensive information on the coronary vasculature to help guide treatment decisions.
      In Infraredx Announces Research Collaboration with Massachusetts General Hospital to Explore New Generation of Cardiovascular Imaging Devices
    3. With our procedure, instead you swallow a capsule. And that capsule captures these microscopic images while you are in the living person. Without taking the tissue out. Not only that but it gathers the microscopic images of the entire esophagus, not just one little spot. So we get a much better understanding and a much better picture of the detailed structure of the esophagus and we are able to get a much better diagnoses.
      In Cancer detection as easy as popping a pill (video)
    4. The images produced have been some of the best we have seen of the esophagus...We originally were concerned that we might miss a lot of data because of the small size of the capsule; but we were surprised to find that, once the pill has been swallowed, it is firmly ‘grasped’ by the esophagus, allowing complete microscopic imaging of the entire wall. Other methods we have tried can compress the esophageal lining, making it difficult to obtain accurate, three-dimensional pictures. The capsule device provides additional key diagnostic information by making it possible to see the surface structure in greater detail.
      In Pill-sized device rivals endoscopy: Novel imaging system screens for Barrett’s esophagus in minutes
    5. OFDI imaging with laser marking has the potential to improve the diagnostic paradigm for patients suspected of having Barrett's esophagus, one of the most common precursors to esophageal cancer... There is a large and growing unmet need to improve the gastroenterologist's ability to detect, diagnose and make critical treatment decisions for patients with Barrett's esophagus, and this technological advancement may significantly improve this paradigm. Provided these results can be confirmed in an ongoing, larger study, OFDI-based guided biopsy may soon be able to help clinicians make more precise and rapid diagnoses while taking fewer, but more targeted, biopsies allowing patients to receive more tailored management for diseases like Barrett's esophagus.
      In NinePoint Medical Announces New Data Presented on Innovative Optical Frequency Domain Imaging Technology at 19th UEGW Meeting
    6. MicroOCT has the contrast and resolution required to investigate the cellular and subcellular components underlying coronary atherosclerosis, the disease that precipitates heart attack...This high level of performance opens up the future possibility of observing these microscopic features in human patients, which has implications for improving the understanding, diagnosis, and therapeutic monitoring of coronary artery disease.
      In A closer look at atherosclerosis: High-res imaging reveals cellular details of coronary arteries
    7. High quality images provided by optical frequency domain imaging – or OFDI – may one day enable physicians to implement routine, less invasive screening procedures for high-risk patients...The ability to perform accurate diagnoses for conditions like Barrett’s esophagus could also provide significant improvements over random biopsies that are currently the standard of care for patients at risk for developing esophageal cancer.
      In NinePoint Medical Licenses 188 Patents and Patent Applications from Massachusetts General Hospital
    8. These results are comparable to what is seen with drug eluting stents in terms of thickness--we did not see a significant hyperplastic injury response.
      In vProtect(TM) Luminal Shield Stabilizes Vulnerable Plaque
    9. The wealth of information that we can now obtain will undoubtedly improve our ability to understand coronary artery disease and may allow cardiologists to diagnose and treat plaque before it leads to serious problems.
      In America wakes up to 3-D human coronary artery imaging